National Medical Products Administration
国家药监局
The National Medical Products Administration (NMPA) is China's national regulatory agency for medical products, including drugs, medical devices, and cosmetics. In elsewhere's corpus, it appears primarily as the approval authority for innovative medical products seeking market access in China.
Per a 2025 Gaorong Ventures piece, Pulnovo Medical's PADN device became "中国首个First-in-Class的原创肺动脉高压医疗器械" (China's first First-in-Class original pulmonary arterial hypertension medical device) upon receiving NMPA approval, marking the start of its commercialization path . Earlier, in 2023, 5Y Capital reported that Abogen Bioscience's mRNA drug candidate ABO2011 received clinical trial approval from the NMPA .
elsewhere's corpus does not contain a direct profile of the NMPA itself; it appears only as a regulatory milestone in coverage of portfolio companies.
AI-generated — may contain errors, please verify.
Coverage
Yixi Dynamics | Yixi Biotech's Fucosyllactose Receives National Medical Products Administration Filing for New Cosmetic Ingredient
Yixi Biotech's fucosyllactose has received cosmetic new ingredient registration from the National Medical Products Administration.
Linear Capital Portfolio Company | Hobot's "Ultrasound Probe Holding and Remote Control System" Receives NMPA Class III Medical Device Registration Certificate
On November 8, "Hobin Intelligence" — a Linear Capital angel-round lead investment — received official approval from the National Medical Products Administration for its "Ultrasound Probe Holding and Remote Control System." This milestone carries significant weight for Hobin Intelligence. *MedRobot* published an in-depth analysis of the development, which we're sharing here.
Li Feng Column | The Trade War Gets a Comma, but China's Secret Weapon Is Just About to Show Its Edge
What makes China's economic experience distinctive is that much of it consists of "the unintended consequences of human action."
